Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9850701 | 0.81 | TSHR (0.55) | TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL539982 | 0.80 | MAP2K1 (0.55) | MAP2K1MAP2K2TDP1L3MBTL1POLB | |
| SCHEMBL9699965 | 0.79 | TSHR (0.57) | TDP1L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL26586889 | 0.78 | POLB (0.39) | MAP2K1MAP2K2TDP1L3MBTL1POLB | |
| SCHEMBL4504422 | 0.78 | TAAR1 (0.36) | MAP2K1MAP2K2TDP1L3MBTL1MAPT | |
| SCHEMBL26586786 | 0.77 | POLB (0.41) | MAP2K1MAP2K2TDP1L3MBTL1POLB | |
| SCHEMBL16868364 | 0.77 | MAP2K1 (0.33) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6215461 | 0.75 | NPC1 (0.41) | L3MBTL1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL7641258 | 0.75 | TSHR (0.46) | TDP1MAPTALDH1A1GAARAB9A | |
| SCHEMBL30778915 | 0.75 | MAP2K1 (0.47) | MAP2K1MAP2K2MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660755-B2 | Controlling cell proliferation agent; skin disorders; antiinflamamtory agents | ALLERGAN, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030109687-A1 | Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity | ALLERGAN, INC. | 2003-06-12 | — | — | US | disclosed |
| US-6455701-B1 | SUCH AS 4-((4'-TERT-BUTYL-3'-(4?-TRIFLUOROMETHYL)PHENOXY) PHENYLETHYNYL)BENZOIC ACID; SIDE EFFECT REDUCTION | ALLERGAN, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6187950-B1 | A REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES | ALLERGAN, INC. | 2001-02-13 | — | — | US | disclosed |
| US-5919970-A | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity | ALLERGAN SALES, INC. (US) | 1999-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109687-A1 | Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity | RXRB, RXRA, RXRG | MAP2K1 2101/4885MAP2K2 2179/4885TDP1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.